Ken Johnson
Chief Tech/Sci/R&D Officer chez XERIS BIOPHARMA HOLDINGS, INC.
Fortune : 987 561 $ au 31/03/2024
Profil
Ken Johnson is currently the Senior VP-Medical Affairs & Global Development at Xeris Biopharma Holdings, Inc. He previously worked as the Executive Director-US Medical Affairs at Merck & Co., Inc. from 2016 to 2017, and as the Vice President-Analytics & Outcomes Research at Caremark Rx, Inc. from 2000 to 2002.
He also held the position of SVP-Clinical Development & Regulatory Affairs at Xeris Pharmaceuticals, Inc. and Vice President-Analytics & Outcomes Research at Caremark LLC.
From 2012 to 2015, he was the Vice President-Medical Affairs & Outcomes Research at Durata Therapeutics, Inc. and at Horizon Pharma, Inc. he held the position of Vice President-Medical Affairs & Outcomes Research.
He was also the Vice President-Medical Affairs & Outcomes Research at Circassia Pharmaceuticals, Inc. from 2015 to 2016.
Dr. Johnson received his doctorate degree from the University of Minnesota in 1987.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/01/2024 | 446 860 ( 0,32% ) | 987 561 $ | 31/03/2024 |
Postes actifs de Ken Johnson
| Sociétés | Poste | Début |
|---|---|---|
| XERIS BIOPHARMA HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 01/10/2021 |
Anciens postes connus de Ken Johnson
| Sociétés | Poste | Fin |
|---|---|---|
| MERCK & CO., INC. | Chief Tech/Sci/R&D Officer | 01/01/2017 |
Circassia Pharmaceuticals, Inc.
 Circassia Pharmaceuticals, Inc. Medical DistributorsDistribution Services Part of Niox Group Plc, Circassia Pharmaceuticals, Inc. is a pharmaceutical company that specializes in the development and commercialization of respiratory products. Circassia Pharmaceuticals is based in Raleigh, NC. The private company's main product, tudorza® pressair®, is an anticholinergic medication used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). | Chief Tech/Sci/R&D Officer | 01/01/2016 |
| DURATA THERAPEUTICS INC | Chief Tech/Sci/R&D Officer | 01/03/2015 |
Caremark Rx, Inc.
 Caremark Rx, Inc. Medical/Nursing ServicesHealth Services Caremark Rx, Inc. provides pharmaceutical and prescription benefit program services. The company primarily sponsors of health benefit plans and individuals located throughout the United States. The company was established in 1993 and is headquartered in Nashville, TN. | Corporate Officer/Principal | 01/01/2002 |
Horizon Pharma, Inc.
 Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | Chief Tech/Sci/R&D Officer | - |
Formation de Ken Johnson
| University of Minnesota | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Caremark Rx, Inc.
Caremark Rx, Inc. Medical/Nursing ServicesHealth Services Caremark Rx, Inc. provides pharmaceutical and prescription benefit program services. The company primarily sponsors of health benefit plans and individuals located throughout the United States. The company was established in 1993 and is headquartered in Nashville, TN. | Health Services |
Xeris Pharmaceuticals, Inc.
 Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | Health Technology |
| Caremark LLC | |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | Health Technology |
Circassia Pharmaceuticals, Inc.
Circassia Pharmaceuticals, Inc. Medical DistributorsDistribution Services Part of Niox Group Plc, Circassia Pharmaceuticals, Inc. is a pharmaceutical company that specializes in the development and commercialization of respiratory products. Circassia Pharmaceuticals is based in Raleigh, NC. The private company's main product, tudorza® pressair®, is an anticholinergic medication used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). | Distribution Services |
| Xeris Biopharma Holdings, Inc. | |
Durata Therapeutics, Inc.
 Durata Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Durata Therapeutics, Inc. develops and commercializes novel therapeutics for infectious diseases and acute illnesses. The company was founded on November 4, 2009 and is headquartered in Chicago, IL. | Health Technology |
